KPRX (Kiora Pharmaceuticals) FFO


KPRX Kiora Pharmaceuticals Inc KPRX
33 GF Score
Price $2.55
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

KPRX
33GF Score
Kiora Pharmaceuticals Inc KPRX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
33GF Score

Get the complete analysis for KPRX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.55
Price